Teladoc Health
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Teladoc Health (TDOC) | 1.36B | -8.66 | 1.05 | 0.00% |
| Veeva Systems (VEEV) | 43.10B | 43.64 | 5.80 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.50B | 33.78 | 5.75 | 0.00% |
| Tempus AI (TEM) | 9.86B | -50.98 | 19.70 | 0.00% |
| Hinge Health (HNGE) | 8.60B | 51.68 | 28.71 | 0.00% |
| HealthEquity (HQY) | 7.84B | 34.21 | 3.94 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 34.4% below Morningstar's fair value estimate.
Fair value
Teladoc Health Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $10.01 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 81.0% falls in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.
Conversely, the company's balance sheet is potentially concerning. Excessive leverage heightens financial risk, potentially undermining a firm's value. The firm's current ratio of 0.9, a core component of leverage, lies in the bottom 20% compared with global peers. This suggests the company may struggle to cope with economic distress and may need to reinvest in additional inventory. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:44:00 · For reference only, not investment advice and not tailored to your situation.
Teladoc Health discussion 0 comments